Cargando…

The Role of Vitamin D(3) as an Independent Predicting Marker for One-Year Mortality in Patients with Acute Heart Failure

Background: Deficiency in vitamin D(3) and its metabolites has been linked to dismal outcomes in patients with chronic diseases, including cardiovascular disease and heart failure (HF). It remains unclear if a vitamin D(3) status is a prognostic feature in patients with acute decompensated HF. Metho...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiele, Kirsten, Cornelissen, Anne, Florescu, Roberta, Kneizeh, Kinan, Brandenburg, Vincent Matthias, Witte, Klaus, Marx, Nikolaus, Schuh, Alexander, Stöhr, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145950/
https://www.ncbi.nlm.nih.gov/pubmed/35628860
http://dx.doi.org/10.3390/jcm11102733
Descripción
Sumario:Background: Deficiency in vitamin D(3) and its metabolites has been linked to dismal outcomes in patients with chronic diseases, including cardiovascular disease and heart failure (HF). It remains unclear if a vitamin D(3) status is a prognostic feature in patients with acute decompensated HF. Methods: We assessed serum levels of 25-OH-vitamin D(3) and 1,25-(OH)(2)-vitamin D(3) in 139 patients with acute HF who had been admitted to the intermediate care unit of a maximum care hospital. The follow-up period was one year. After exclusion of patients with sampling errors and those who were lost to follow-up, 118 patients remained in the final study cohort. Outcome estimates by 25-OH-vitamin D(3) and 1,25-(OH)(2)-vitamin D(3) levels were compared to the Seattle Heart Failure (SHF) Model. Results: More than two-thirds (79.7%) of the patients showed inadequate 25-OH-vitamin D(3) levels (i.e., <30 ng/mL) upon admission. Low levels of 1,25-(OH)(2)-vitamin D(3) (i.e., <19.9 pg/mL) were observed in 16.1% of patients. Of the 118 HF patients, 22 (19%) died during the following 12 months. There were no differences in vitamin D(3) levels between patients who died and those who survived, neither in 25-OH-vitamin D(3) (23.37 ± 19.14 ng/mL vs. 19.11 ± 12.25 ng/mL; p = 0.19) nor in 1,25-(OH)(2)-vitamin D(3) levels (31.10 ± 19.75 ng/mL vs. 38.25 ± 15.73 ng/mL; p = 0.02); therefore, vitamin D(3) levels alone did not predict one-year survival (AUC [25-OH-vitamin D(3)] 0.50; 95% CI 0.34–0.65; AUC [1,25-(OH)2-vitamin D(3)] 0.62; 95% CI 0.48–0.76). Moreover, whilst the SHF model exhibited acceptable discriminatory ability for predicting one-year mortality (AUC 0.79; 95% CI 0.66–0.91), adding vitamin D levels on admission to the SHF score did not improve its discriminatory value. Conclusion: Our data do not support the use of vitamin D(3) screening in patients admitted with acute decompensated HF to aid prognostication.